An Evaluation of Treatment Patterns and Associated Outcomes Among Adult Hospitalized Patients With Lower-Risk Community-Acquired Complicated Intra-abdominal Infections: How Often Are Expert Guidelines Followed?

cIAI infection outcomes treatment

Journal

Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045

Informations de publication

Date de publication:
Jul 2020
Historique:
received: 31 03 2020
accepted: 12 06 2020
entrez: 18 7 2020
pubmed: 18 7 2020
medline: 18 7 2020
Statut: epublish

Résumé

Expert guidelines discourage use of antipseudomonal β-lactams and fluoroquinolones in lower-risk patients with community-acquired complicated intra-abdominal infection (CA cIAI). Compliance with these recommendations across US hospitals is unclear. This study sought to determine treatment patterns and associated outcomes among adult hospitalized lower-risk patients with CA cIAI. A study using data from the Premier Healthcare Database (10/2015-12/2017) was performed. Inclusion criteria: age ≥18 years; hospitalized; had a cIAI at admission; and received antibiotics within the first 4 hospital days. Patients were excluded if they were high risk, were transferred from another health care facility, had a recent hospital admission, or received dialysis within 30 days of admission. Empiric antibiotic treatment patterns and associated outcomes were quantified. Overall, 46 Overuse of antipseudomonal β-lactams and fluoroquinolones was commonplace among lower-risk CA IAI patients. These findings can serve as the basis for an antimicrobial stewardship initiative in hospitals aspiring to reduce the use of broad-spectrum antibiotics.

Sections du résumé

BACKGROUND BACKGROUND
Expert guidelines discourage use of antipseudomonal β-lactams and fluoroquinolones in lower-risk patients with community-acquired complicated intra-abdominal infection (CA cIAI). Compliance with these recommendations across US hospitals is unclear. This study sought to determine treatment patterns and associated outcomes among adult hospitalized lower-risk patients with CA cIAI.
METHODS METHODS
A study using data from the Premier Healthcare Database (10/2015-12/2017) was performed. Inclusion criteria: age ≥18 years; hospitalized; had a cIAI at admission; and received antibiotics within the first 4 hospital days. Patients were excluded if they were high risk, were transferred from another health care facility, had a recent hospital admission, or received dialysis within 30 days of admission. Empiric antibiotic treatment patterns and associated outcomes were quantified.
RESULTS RESULTS
Overall, 46
CONCLUSIONS CONCLUSIONS
Overuse of antipseudomonal β-lactams and fluoroquinolones was commonplace among lower-risk CA IAI patients. These findings can serve as the basis for an antimicrobial stewardship initiative in hospitals aspiring to reduce the use of broad-spectrum antibiotics.

Identifiants

pubmed: 32676511
doi: 10.1093/ofid/ofaa237
pii: ofaa237
pmc: PMC7353956
doi:

Types de publication

Journal Article

Langues

eng

Pagination

ofaa237

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

Références

Clin Infect Dis. 2017 Aug 15;65(4):613-618
pubmed: 28444166
Infect Control Hosp Epidemiol. 2007 Aug;28(8):959-65
pubmed: 17620244
J Microbiol Immunol Infect. 2018 Jun;51(3):359-366
pubmed: 28988663
JAMA Surg. 2017 Mar 1;152(3):224-232
pubmed: 27851857
Surg Infect (Larchmt). 2019 Dec;20(8):650-657
pubmed: 31464573
World J Emerg Surg. 2014 May 14;9:37
pubmed: 24883079
Clin Infect Dis. 2018 Mar 19;66(7):e1-e48
pubmed: 29462280
Clin Infect Dis. 2010 Oct 15;51(8):895-903
pubmed: 20839951
J Chemother. 2015 Feb;27(2):67-73
pubmed: 24548089
Clin Infect Dis. 2010 Jan 15;50(2):133-64
pubmed: 20034345
Open Forum Infect Dis. 2019 Nov 04;6(12):ofz475
pubmed: 31844636
Surg Infect (Larchmt). 2017 Jan;18(1):1-76
pubmed: 28085573
Open Forum Infect Dis. 2019 Nov 25;6(12):ofz504
pubmed: 31858017
J Clin Med. 2019 Jun 17;8(6):
pubmed: 31212991
Pharmacotherapy. 2019 Mar;39(3):261-270
pubmed: 30506852
J Antimicrob Chemother. 2014 Apr;69(4):1127-31
pubmed: 24327619
Int J Surg. 2010;8(6):426-9
pubmed: 20621208
J Trauma Acute Care Surg. 2012 Mar;72(3):691-5
pubmed: 22491554
Clin Infect Dis. 2016 May 15;62(10):e51-77
pubmed: 27080992
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Clin Infect Dis. 2019 Aug 30;69(6):921-929
pubmed: 30561562
J Antimicrob Chemother. 2011 Jul;66(7):1600-8
pubmed: 21508008
Arch Intern Med. 2012 Jun 25;172(12):922-8
pubmed: 22732747
Clin Infect Dis. 2019 Aug 1;69(4):604-613
pubmed: 30383203

Auteurs

Thomas P Lodise (TP)

Albany College of Pharmacy and Health Sciences, Albany, New York, USA.

Sergey Izmailyan (S)

Tetraphase Pharmaceuticals, Inc., Watertown, Massachusetts, USA.

Melanie Olesky (M)

Tetraphase Pharmaceuticals, Inc., Watertown, Massachusetts, USA.

Kenneth Lawrence (K)

Tetraphase Pharmaceuticals, Inc., Watertown, Massachusetts, USA.

Classifications MeSH